Last reviewed · How we verify

NCT06975631

Post-market Study on TrHCROSS® in Knee Osteoarthritis After a Single Injection

Completed NA Last updated 21 May 2025
What this trial tests

NA trial testing TrHCROSS® in Knee Osteoarthritis in 60 participants. Completed in 14 February 2024.

Timeline
2 June 2022
Primary endpoint
10 August 2023
14 February 2024

Quick facts

Lead sponsori+Med S.Coop.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment60
Start date2 June 2022
Primary completion10 August 2023
Estimated completion14 February 2024
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

i+Med S.Coop. — full company profile →

Who can join

Adults 18 to 80, any sex, with Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Double-blind study assessing the safety and efficacy of TrHCROSS® in knee osteoarthritis, compared to Hyalone®, using scales such as WOMAC, VAS, and KOOS. The population includes 60 symptomatic patients with mild to moderate KOA (Kellgren-Lawrence II or III) who have not responded adequately to non-pharmacological treatments or simple analgesics.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Knee Osteoarthritis

Currently open trials in the same condition.

Other i+Med S.Coop. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06975631.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing